ID   S29A4_HUMAN             Reviewed;         530 AA.
AC   Q7RTT9; Q6PJ08; Q86WY8; Q8NAR3; Q8NBM2;
DT   18-MAR-2008, integrated into UniProtKB/Swiss-Prot.
DT   15-DEC-2003, sequence version 1.
DT   07-APR-2021, entry version 139.
DE   RecName: Full=Equilibrative nucleoside transporter 4;
DE            Short=hENT4;
DE   AltName: Full=Plasma membrane monoamine transporter;
DE   AltName: Full=Solute carrier family 29 member 4;
GN   Name=SLC29A4; Synonyms=ENT4, PMAT; ORFNames=PSEC0113;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION,
RP   TOPOLOGY, AND TISSUE SPECIFICITY.
RC   TISSUE=Kidney;
RX   PubMed=15448143; DOI=10.1074/jbc.m407913200;
RA   Engel K., Zhou M., Wang J.;
RT   "Identification and characterization of a novel monoamine transporter in
RT   the human brain.";
RL   J. Biol. Chem. 279:50042-50049(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANTS
RP   GLU-79; LYS-124 AND THR-429.
RC   TISSUE=Brain, and Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   IDENTIFICATION.
RX   PubMed=12446811; DOI=10.1093/oxfordjournals.molbev.a004044;
RA   Acimovic Y., Coe I.R.;
RT   "Molecular evolution of the equilibrative nucleoside transporter family:
RT   identification of novel family members in prokaryotes and eukaryotes.";
RL   Mol. Biol. Evol. 19:2199-2210(2002).
RN   [6]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, GLYCOSYLATION AT
RP   ASN-523, AND MUTAGENESIS OF GLU-206 AND GLU-375.
RX   PubMed=16873718; DOI=10.1161/01.res.0000238359.18495.42;
RA   Barnes K., Dobrzynski H., Foppolo S., Beal P.R., Ismat F., Scullion E.R.,
RA   Sun L., Tellez J., Ritzel M.W., Claycomb W.C., Cass C.E., Young J.D.,
RA   Billeter-Clark R., Boyett M.R., Baldwin S.A.;
RT   "Distribution and functional characterization of equilibrative nucleoside
RT   transporter-4, a novel cardiac adenosine transporter activated at acidic
RT   pH.";
RL   Circ. Res. 99:510-519(2006).
RN   [7]
RP   FUNCTION, TOPOLOGY, AND TISSUE SPECIFICITY.
RX   PubMed=17018840; DOI=10.1152/ajprenal.00302.2006;
RA   Xia L., Engel K., Zhou M., Wang J.;
RT   "Membrane localization and pH-dependent transport of a newly cloned organic
RT   cation transporter (PMAT) in kidney cells.";
RL   Am. J. Physiol. 292:F682-F690(2007).
RN   [8]
RP   FUNCTION, AND MUTAGENESIS OF ASP-91; ASP-107; GLU-128; ASP-154; ASP-163;
RP   GLU-206; THR-220; GLU-227; GLU-242; TRP-336 AND GLU-375.
RX   PubMed=17121826; DOI=10.1074/jbc.m609421200;
RA   Zhou M., Xia L., Engel K., Wang J.;
RT   "Molecular determinants of substrate selectivity of a novel organic cation
RT   transporter (PMAT) in the SLC29 family.";
RL   J. Biol. Chem. 282:3188-3195(2007).
RN   [9]
RP   TISSUE SPECIFICITY.
RX   PubMed=17393420; DOI=10.1002/mrd.20697;
RA   Bottalico B., Noskova V., Pilka R., Larsson I., Domanski H., Casslen B.,
RA   Hansson S.R.;
RT   "The organic cation transporters (OCT1, OCT2, EMT) and the plasma membrane
RT   monoamine transporter (PMAT) show differential distribution and cyclic
RT   expression pattern in human endometrium and early pregnancy decidua.";
RL   Mol. Reprod. Dev. 74:1303-1311(2007).
CC   -!- FUNCTION: Functions as a polyspecific organic cation transporter,
CC       efficiently transporting many organic cations such as monoamine
CC       neurotransmitters 1-methyl-4-phenylpyridinium and biogenic amines
CC       including serotonin, dopamine, norepinephrine and epinephrine. May play
CC       a role in regulating central nervous system homeostasis of monoamine
CC       neurotransmitters. May be involved in luminal transport of organic
CC       cations in the kidney and seems to use luminal proton gradient to drive
CC       organic cation reabsorption. Does not seem to transport nucleoside and
CC       nucleoside analogs such as uridine, cytidine, thymidine, adenosine,
CC       inosine, guanosine, and azidothymidine. In (PubMed:16873718) adenosine
CC       is efficiently transported but in a fashion highly sensitive to
CC       extracellular pH, with maximal activity in the pH range 5.5 to 6.5.
CC       Glu-206 is essential for the cation selectivity and may function as the
CC       charge sensor for cationic substrates. Transport is chloride and
CC       sodium-independent but appears to be sensitive to changes in membrane
CC       potential. Weakly inhibited by the classical inhibitors of
CC       equilibrative nucleoside transport, dipyridamole, dilazep, and
CC       nitrobenzylthioinosine. May play a role in the regulation of
CC       extracellular adenosine concentrations in cardiac tissues, in
CC       particular during ischemia. {ECO:0000269|PubMed:15448143,
CC       ECO:0000269|PubMed:16873718, ECO:0000269|PubMed:17018840,
CC       ECO:0000269|PubMed:17121826}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Multi-pass membrane
CC       protein {ECO:0000305}. Apical cell membrane {ECO:0000305}; Multi-pass
CC       membrane protein {ECO:0000305}. Note=Located to the plasma membranes of
CC       ventricular myocytes and vascular endothelial cells. Targeted to the
CC       apical membranes of differentiated kidney epithelial cells.
CC       {ECO:0000269|PubMed:15448143, ECO:0000269|PubMed:16873718}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q7RTT9-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q7RTT9-2; Sequence=VSP_032647;
CC   -!- TISSUE SPECIFICITY: Expressed abundantly in the heart, in both
CC       cardiomyocytes and vascular endothelial cells (at protein level).
CC       Highly expressed in brain, kidney and skeletal muscle. In the brain
CC       expressed in cerebellum, cerebral cortex, medulla, occipital pole,
CC       frontal and temporal lobes putamen and in the spinal cord. Lower
CC       expression in liver, pancreas, and liver. Expressed in endometrial
CC       tissue, exclusively in the stroma. Expression is high in the
CC       proliferative phase, decreases during the secretory phase, and is no
CC       longer detectable in the menstrual phase. {ECO:0000269|PubMed:15448143,
CC       ECO:0000269|PubMed:16873718, ECO:0000269|PubMed:17018840,
CC       ECO:0000269|PubMed:17393420}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:16873718}.
CC   -!- SIMILARITY: Belongs to the SLC29A/ENT transporter (TC 2.A.57) family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAC11612.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY485959; AAS65965.1; -; mRNA.
DR   EMBL; AK075422; BAC11612.1; ALT_INIT; mRNA.
DR   EMBL; AK092242; BAC03836.1; -; mRNA.
DR   EMBL; CH471144; EAW87329.1; -; Genomic_DNA.
DR   EMBL; CH471144; EAW87330.1; -; Genomic_DNA.
DR   EMBL; BC025325; AAH25325.1; -; mRNA.
DR   EMBL; BC047592; AAH47592.1; -; mRNA.
DR   EMBL; BK000627; DAA00308.1; -; Genomic_DNA.
DR   CCDS; CCDS5340.1; -. [Q7RTT9-1]
DR   CCDS; CCDS75561.1; -. [Q7RTT9-2]
DR   RefSeq; NP_001035751.1; NM_001040661.1. [Q7RTT9-1]
DR   RefSeq; NP_001287776.1; NM_001300847.1. [Q7RTT9-2]
DR   RefSeq; NP_694979.2; NM_153247.2. [Q7RTT9-1]
DR   RefSeq; XP_005249715.1; XM_005249658.4. [Q7RTT9-2]
DR   RefSeq; XP_006715730.1; XM_006715667.3. [Q7RTT9-1]
DR   RefSeq; XP_011513502.1; XM_011515200.2. [Q7RTT9-1]
DR   RefSeq; XP_011513503.1; XM_011515201.2. [Q7RTT9-1]
DR   BioGRID; 128822; 1.
DR   IntAct; Q7RTT9; 1.
DR   STRING; 9606.ENSP00000380081; -.
DR   ChEMBL; CHEMBL3509593; -.
DR   DrugBank; DB00331; Metformin.
DR   DrugBank; DB01104; Sertraline.
DR   DrugCentral; Q7RTT9; -.
DR   GuidetoPHARMACOLOGY; 1120; -.
DR   TCDB; 2.A.57.1.5; the equilibrative nucleoside transporter (ent) family.
DR   GlyGen; Q7RTT9; 1 site.
DR   iPTMnet; Q7RTT9; -.
DR   PhosphoSitePlus; Q7RTT9; -.
DR   BioMuta; SLC29A4; -.
DR   DMDM; 74713147; -.
DR   PaxDb; Q7RTT9; -.
DR   PeptideAtlas; Q7RTT9; -.
DR   PRIDE; Q7RTT9; -.
DR   ProteomicsDB; 68902; -. [Q7RTT9-1]
DR   ProteomicsDB; 68903; -. [Q7RTT9-2]
DR   Antibodypedia; 24590; 255 antibodies.
DR   Ensembl; ENST00000297195; ENSP00000297195; ENSG00000164638. [Q7RTT9-1]
DR   Ensembl; ENST00000396872; ENSP00000380081; ENSG00000164638. [Q7RTT9-1]
DR   Ensembl; ENST00000406453; ENSP00000385845; ENSG00000164638. [Q7RTT9-2]
DR   GeneID; 222962; -.
DR   KEGG; hsa:222962; -.
DR   UCSC; uc003soc.4; human. [Q7RTT9-1]
DR   CTD; 222962; -.
DR   DisGeNET; 222962; -.
DR   GeneCards; SLC29A4; -.
DR   HGNC; HGNC:23097; SLC29A4.
DR   HPA; ENSG00000164638; Tissue enhanced (adipose).
DR   MIM; 609149; gene.
DR   neXtProt; NX_Q7RTT9; -.
DR   OpenTargets; ENSG00000164638; -.
DR   PharmGKB; PA134976472; -.
DR   VEuPathDB; HostDB:ENSG00000164638.10; -.
DR   eggNOG; KOG1479; Eukaryota.
DR   GeneTree; ENSGT00950000182898; -.
DR   HOGENOM; CLU_021611_4_0_1; -.
DR   InParanoid; Q7RTT9; -.
DR   OMA; VIFDMSV; -.
DR   OrthoDB; 674800at2759; -.
DR   PhylomeDB; Q7RTT9; -.
DR   TreeFam; TF313950; -.
DR   PathwayCommons; Q7RTT9; -.
DR   Reactome; R-HSA-83936; Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane.
DR   BioGRID-ORCS; 222962; 20 hits in 987 CRISPR screens.
DR   ChiTaRS; SLC29A4; human.
DR   GeneWiki; SLC29A4; -.
DR   GenomeRNAi; 222962; -.
DR   Pharos; Q7RTT9; Tchem.
DR   PRO; PR:Q7RTT9; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; Q7RTT9; protein.
DR   Bgee; ENSG00000164638; Expressed in buccal mucosa cell and 158 other tissues.
DR   ExpressionAtlas; Q7RTT9; baseline and differential.
DR   Genevisible; Q7RTT9; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:ARUK-UCL.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:ARUK-UCL.
DR   GO; GO:0016021; C:integral component of membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:ARUK-UCL.
DR   GO; GO:0098793; C:presynapse; IEA:GOC.
DR   GO; GO:0008324; F:cation transmembrane transporter activity; ISS:ARUK-UCL.
DR   GO; GO:0015562; F:efflux transmembrane transporter activity; IMP:ARUK-UCL.
DR   GO; GO:0008504; F:monoamine transmembrane transporter activity; IDA:ARUK-UCL.
DR   GO; GO:0005326; F:neurotransmitter transmembrane transporter activity; IDA:ARUK-UCL.
DR   GO; GO:0005337; F:nucleoside transmembrane transporter activity; IEA:InterPro.
DR   GO; GO:0005342; F:organic acid transmembrane transporter activity; IDA:ARUK-UCL.
DR   GO; GO:0015101; F:organic cation transmembrane transporter activity; IDA:ARUK-UCL.
DR   GO; GO:0019534; F:toxin transmembrane transporter activity; ISS:ARUK-UCL.
DR   GO; GO:0042910; F:xenobiotic transmembrane transporter activity; IDA:ARUK-UCL.
DR   GO; GO:0098655; P:cation transmembrane transport; ISS:ARUK-UCL.
DR   GO; GO:0090494; P:dopamine uptake; IDA:ARUK-UCL.
DR   GO; GO:0051625; P:epinephrine uptake; IDA:ARUK-UCL.
DR   GO; GO:0140115; P:export across plasma membrane; IMP:ARUK-UCL.
DR   GO; GO:0001692; P:histamine metabolic process; TAS:ARUK-UCL.
DR   GO; GO:0051615; P:histamine uptake; IDA:ARUK-UCL.
DR   GO; GO:0015844; P:monoamine transport; IMP:ARUK-UCL.
DR   GO; GO:0006836; P:neurotransmitter transport; IDA:ARUK-UCL.
DR   GO; GO:0051620; P:norepinephrine uptake; IDA:ARUK-UCL.
DR   GO; GO:1903825; P:organic acid transmembrane transport; IDA:ARUK-UCL.
DR   GO; GO:0015695; P:organic cation transport; IDA:ARUK-UCL.
DR   GO; GO:0051610; P:serotonin uptake; IDA:ARUK-UCL.
DR   GO; GO:1901998; P:toxin transport; ISS:ARUK-UCL.
DR   GO; GO:0150104; P:transport across blood-brain barrier; NAS:ARUK-UCL.
DR   GO; GO:0042908; P:xenobiotic transport; IDA:ARUK-UCL.
DR   InterPro; IPR030198; ENT4.
DR   InterPro; IPR002259; Eqnu_transpt.
DR   InterPro; IPR036259; MFS_trans_sf.
DR   PANTHER; PTHR10332; PTHR10332; 1.
DR   PANTHER; PTHR10332:SF4; PTHR10332:SF4; 1.
DR   Pfam; PF01733; Nucleoside_tran; 1.
DR   PIRSF; PIRSF016379; ENT; 1.
DR   PRINTS; PR01130; DERENTRNSPRT.
DR   SUPFAM; SSF103473; SSF103473; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Glycoprotein; Membrane;
KW   Reference proteome; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..530
FT                   /note="Equilibrative nucleoside transporter 4"
FT                   /id="PRO_0000326251"
FT   TOPO_DOM        1..68
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        69..89
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        90..101
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        102..122
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        123..139
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        140..160
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        161..166
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        167..187
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        188..231
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        232..252
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        253..351
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        352..372
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        373..381
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        382..402
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        403..416
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        417..437
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        438..450
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        451..471
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        472..486
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        487..509
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        510..530
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        523
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         139..182
FT                   /note="GYLLALGPLLFISICDVWLQLFSRDQAYAINLAAVGTVAFGCTV -> ASAT
FT                   CGCSSSLGTRPTPSTWPLWAPWPSAA (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_032647"
FT   VARIANT         79
FT                   /note="V -> E (in dbSNP:rs17854505)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_040044"
FT   VARIANT         124
FT                   /note="N -> K (in dbSNP:rs17855675)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_040045"
FT   VARIANT         429
FT                   /note="P -> T (in dbSNP:rs17857336)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_040046"
FT   MUTAGEN         91
FT                   /note="D->A: No significant change in cationic transport
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:17121826"
FT   MUTAGEN         107
FT                   /note="D->A: Loss of cationic transport activity."
FT                   /evidence="ECO:0000269|PubMed:17121826"
FT   MUTAGEN         128
FT                   /note="E->A: No significant change in cationic transport
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:17121826"
FT   MUTAGEN         154
FT                   /note="D->A: Loss of cationic transport activity; increase
FT                   in uridine uptake."
FT                   /evidence="ECO:0000269|PubMed:17121826"
FT   MUTAGEN         163
FT                   /note="D->A: Loss of cationic transport activity."
FT                   /evidence="ECO:0000269|PubMed:17121826"
FT   MUTAGEN         206
FT                   /note="E->A: Loss of cationic transport activity."
FT                   /evidence="ECO:0000269|PubMed:16873718,
FT                   ECO:0000269|PubMed:17121826"
FT   MUTAGEN         206
FT                   /note="E->D: No loss of cationic transporter activity; no
FT                   activity towards uridine."
FT                   /evidence="ECO:0000269|PubMed:16873718,
FT                   ECO:0000269|PubMed:17121826"
FT   MUTAGEN         206
FT                   /note="E->Q: Loss of cationic transporter activity;
FT                   increase in uridine uptake."
FT                   /evidence="ECO:0000269|PubMed:16873718,
FT                   ECO:0000269|PubMed:17121826"
FT   MUTAGEN         206
FT                   /note="E->R: Loss of cationic transporter activity."
FT                   /evidence="ECO:0000269|PubMed:16873718,
FT                   ECO:0000269|PubMed:17121826"
FT   MUTAGEN         220
FT                   /note="T->A: Reduced cationic transport activity."
FT                   /evidence="ECO:0000269|PubMed:17121826"
FT   MUTAGEN         220
FT                   /note="T->I: Loss of cationic transporter activity."
FT                   /evidence="ECO:0000269|PubMed:17121826"
FT   MUTAGEN         220
FT                   /note="T->S: Reduced cationic transport activity."
FT                   /evidence="ECO:0000269|PubMed:17121826"
FT   MUTAGEN         227
FT                   /note="E->A: Functional with slight increased cationic
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:17121826"
FT   MUTAGEN         242
FT                   /note="E->A: Reduced cationic transport activity."
FT                   /evidence="ECO:0000269|PubMed:17121826"
FT   MUTAGEN         336
FT                   /note="W->A: Loss of cationic transport activity."
FT                   /evidence="ECO:0000269|PubMed:17121826"
FT   MUTAGEN         375
FT                   /note="E->A: Functional with slight increased cationic
FT                   transport activity."
FT                   /evidence="ECO:0000269|PubMed:16873718,
FT                   ECO:0000269|PubMed:17121826"
FT   MUTAGEN         375
FT                   /note="E->Q: No change in cationic activity and pH
FT                   sensitivity."
FT                   /evidence="ECO:0000269|PubMed:16873718,
FT                   ECO:0000269|PubMed:17121826"
FT   CONFLICT        25
FT                   /note="S -> C (in Ref. 2; BAC03836)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        41
FT                   /note="Q -> R (in Ref. 2; BAC03836)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        196
FT                   /note="K -> R (in Ref. 2; BAC03836)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        261
FT                   /note="Y -> H (in Ref. 2; BAC11612)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        301
FT                   /note="L -> P (in Ref. 2; BAC03836)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   530 AA;  58059 MW;  3FE5D5ED1D248A13 CRC64;
     MGSVGSQRLE EPSVAGTPDP GVVMSFTFDS HQLEEAAEAA QGQGLRARGV PAFTDTTLDE
     PVPDDRYHAI YFAMLLAGVG FLLPYNSFIT DVDYLHHKYP GTSIVFDMSL TYILVALAAV
     LLNNVLVERL TLHTRITAGY LLALGPLLFI SICDVWLQLF SRDQAYAINL AAVGTVAFGC
     TVQQSSFYGY TGMLPKRYTQ GVMTGESTAG VMISLSRILT KLLLPDERAS TLIFFLVSVA
     LELLCFLLHL LVRRSRFVLF YTTRPRDSHR GRPGLGRGYG YRVHHDVVAG DVHFEHPAPA
     LAPNESPKDS PAHEVTGSGG AYMRFDVPRP RVQRSWPTFR ALLLHRYVVA RVIWADMLSI
     AVTYFITLCL FPGLESEIRH CILGEWLPIL IMAVFNLSDF VGKILAALPV DWRGTHLLAC
     SCLRVVFIPL FILCVYPSGM PALRHPAWPC IFSLLMGISN GYFGSVPMIL AAGKVSPKQR
     ELAGNTMTVS YMSGLTLGSA VAYCTYSLTR DAHGSCLHAS TANGSILAGL
//
